📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Lupin Appoints FMCG Veteran Anand Kripalu as Independent Director for 5-Year Term
Lupin Limited has announced the appointment of Mr. Anand Kripalu as an Additional Director (Non-Executive, Independent) effective February 1, 2026. Mr. Kripalu brings over 30 years of extensive industry experience, having previously served as MD & CEO of Diageo India and held senior leadership roles at Mondelez and Unilever. His appointment is for a five-year term ending January 31, 2031, subject to shareholder approval. This move is expected to enhance the board's strategic depth given his track record in global consumer-facing industries.
Key Highlights
Appointment of Mr. Anand Kripalu as Independent Director for a 5-year term starting February 1, 2026
Over 30 years of leadership experience in FMCG, including roles at Diageo, Mondelez, and Unilever
Educational background includes B.Tech from IIT Madras, MBA from IIM Calcutta, and AMP from Wharton
Currently serves as Executive Director of EPL Limited and holds board positions at Swiggy and United Breweries
The appointment was unanimously approved by the Board based on the Nomination and Remuneration Committee's recommendation
💼 Action for Investors
Investors should view this as a positive step toward strengthening corporate governance and strategic oversight. No immediate portfolio action is required based on this board-level appointment.
Lupin Extends Timeline for VISUfarma B.V. Acquisition to February 2026
Lupin Limited's wholly owned subsidiary, Nanomi B.V., has announced a delay in the acquisition of 100% share capital of VISUfarma B.V., Netherlands. The transaction, which was originally expected to be consummated by the end of calendar year 2025, is now slated for completion by February 28, 2026. The acquisition process is currently in progress and remains subject to specific closing conditions. This update follows the initial definitive agreement signed on September 29, 2025.
Key Highlights
Acquisition of 100% share capital of Amsterdam-based VISUfarma B.V. by Nanomi B.V.
Completion deadline extended from December 31, 2025, to February 28, 2026.
The transaction is currently in progress and pending certain closing conditions.
Initial definitive agreement for the acquisition was signed on September 29, 2025.
💼 Action for Investors
Investors should view this as a minor administrative delay in the acquisition process. Monitor for the final completion announcement by February 2026 to ensure the strategic expansion into the European market remains on track.
Lupin Signs Exclusive Deal for First-in-Class Fortnightly GLP-1 Agonist in India
Lupin has entered into an exclusive licensing agreement with Gan & Lee Pharmaceuticals to commercialize Bofanglutide, a novel GLP-1 receptor agonist, in India. The drug is a potential first-in-class fortnightly (once every two weeks) injection for Type 2 diabetes and obesity management. This partnership targets a massive addressable market in India, which includes approximately 90 million diabetics and 174 million overweight adults. By offering a 50% reduction in injection frequency compared to weekly alternatives, Lupin aims to capture significant market share in the high-growth metabolic health segment.
Key Highlights
Exclusive rights to commercialize Bofanglutide, a fortnightly GLP-1 receptor agonist, in the Indian market.
Reduces injection frequency by 50% compared to existing weekly GLP-1 injectable alternatives.
Targets a massive patient base of 90 million diabetics and 174 million overweight adults in India.
Clinical data indicates weight loss efficacy comparable to or better than current GLP-1 class drugs.
Strengthens Lupin's chronic disease portfolio and establishes a foothold in the lucrative obesity segment.
💼 Action for Investors
Investors should monitor the regulatory approval timeline for Bofanglutide in India as it represents a significant growth lever for Lupin's domestic formulations business. The unique fortnightly dosing provides a strong competitive moat in the rapidly expanding GLP-1 market.
Lupin Signs Exclusive Licensing Deal for Plasil® in Philippines and Brazil
Lupin Limited has entered into an exclusive licensing agreement with Italy-based Neopharmed Gentili S.p.A for the gastroenterology brand Plasil® (metoclopramide). The agreement covers marketing and promotional rights in the Philippines and Brazil through Lupin's subsidiaries, Multicare Pharmaceuticals and MedQuimica. A key strategic component includes shifting the production for the Brazilian market to Lupin's own Medquimica manufacturing facility. This move is designed to strengthen Lupin's gastrointestinal portfolio and presence in high-growth emerging markets.
Key Highlights
Exclusive licensing for the gastroenterology brand Plasil® in the Philippines and Brazil.
Partnership with Neopharmed Gentili S.p.A to leverage local commercial capabilities.
Localization of manufacturing for the Brazilian market at Lupin's Medquimica facility.
Strategic expansion into the anti-emetic and motility disorder treatment segment in emerging markets.
💼 Action for Investors
Investors should monitor the revenue contribution from these new territories as Lupin leverages its existing distribution network. The shift to in-house manufacturing in Brazil could potentially lead to better margins for this product line over time.
Lupin Receives Positive CHMP Opinion for Biosimilar Ranibizumab in Europe
Lupin has received a positive recommendation from the EMA's CHMP for its biosimilar ranibizumab, Ranluspec, for treating various retinal diseases. The recommendation is based on a successful 600-patient global phase III clinical trial demonstrating similarity to the reference product. Once the European Commission grants final approval, the product will be commercialized by Sandoz Group AG across most of the EU. This milestone marks a significant expansion of Lupin's biologics portfolio into the European market.
Key Highlights
Received positive CHMP opinion for biosimilar ranibizumab (Ranluspec) for vial and pre-filled syringe.
Clinical similarity confirmed through a 600-patient global phase III trial across US, EU, Russia, and India.
Partnership with Sandoz Group AG for commercialization in the EU (excluding Germany).
Indications include wet AMD, diabetic macular edema, and retinal vein occlusion.
💼 Action for Investors
This is a significant regulatory win that paves the way for entry into the lucrative European biologics market. Investors should monitor the final EC approval and the subsequent commercial rollout by Sandoz for revenue impact.
Lupin Secures SBTi Validation; Targets 42% Scope 1 & 2 Emission Reduction by FY 2030
Lupin Limited has received official validation from the Science Based Targets initiative (SBTi) for its greenhouse gas emission reduction targets across all three scopes. The company aims to reduce absolute Scope 1 and 2 emissions by 42.0% by FY 2030, using FY 2023 as the base year. Additionally, it has committed to a 61.07% reduction in Scope 3 emissions by FY 2033 from an FY 2024 baseline. This validation aligns Lupin with the Paris Agreement's 1.5°C goal and significantly enhances its ESG profile for global institutional investors.
Key Highlights
Validated target to reduce absolute Scope 1 and 2 GHG emissions by 42.0% by FY 2030 from a FY 2023 base.
Committed to a 61.07% reduction in Scope 3 GHG emissions by FY 2033 from a FY 2024 baseline.
Targets are aligned with the 1.5°C pathway, the most ambitious goal of the Paris Agreement.
Validation covers comprehensive categories including purchased goods, fuel-related activities, and transportation.
Achieved SBTi validation within one year of setting initial climate targets.
💼 Action for Investors
Investors should recognize this as a strengthening of Lupin's ESG credentials, which is increasingly critical for attracting global institutional capital. Monitor how the company balances the capital expenditure required for renewable energy and low-carbon technologies with its operational margins.
Lupin Manufacturing Solutions & PolyPeptide Announce Strategic Alliance
Lupin Manufacturing Solutions (LMS), a subsidiary of Lupin Limited, has announced a strategic alliance with PolyPeptide Group AG to scale the global peptide supply chain. This collaboration aims to enhance supply chain resilience and improve operational efficiency. The partnership will focus on expanding sourcing options to meet rising global demand for peptide APIs. LMS has a team of 250+ scientists.
Key Highlights
Lupin Manufacturing Solutions (LMS) is a 100% subsidiary of Lupin Limited.
PolyPeptide runs a global network of six GMP-certified facilities.
LMS has a team of 250+ scientists.
PolyPeptide's shares are listed on SIX Swiss Exchange (SIX: PPGN).
💼 Action for Investors
Investors should monitor the progress of this strategic alliance and its potential impact on Lupin's long-term growth in the peptide market. This partnership could strengthen Lupin's position as a CDMO supplier.
Lupin Receives Tentative U.S. FDA Approval for Siponimod Tablets
Lupin has received tentative approval from the U.S. FDA for Siponimod Tablets (0.25 mg, 1 mg and 2 mg), bioequivalent to Novartis' Mayzent®. These tablets are indicated for relapsing forms of multiple sclerosis. The product will be manufactured at Lupin’s Pithampur facility in India. Siponimod Tablets (RLD Mayzent®) had estimated annual sales of USD 195 million in the U.S. (IQVIA MAT October 2025).
Key Highlights
Received tentative U.S. FDA approval for Siponimod Tablets
Siponimod Tablets are bioequivalent to Mayzent® Tablets of Novartis
Indicated for treatment of relapsing forms of multiple sclerosis (MS)
Estimated annual sales of Siponimod Tablets (RLD Mayzent®) were USD 195 million in the U.S.
💼 Action for Investors
This tentative approval is a positive sign for Lupin, potentially opening up a significant market opportunity. Investors should monitor the progress of the final approval and launch of this product.
Lupin Gets U.S. FDA Approval for First Biosimilar Armlupeg™ Targeting $1.3 Billion Market
Lupin Limited has achieved a major milestone with the U.S. FDA approval of Armlupeg™, its first biosimilar for the U.S. market. The product is a biosimilar to Neulasta® (Pegfilgrastim) and targets a substantial market with estimated annual U.S. sales of USD 1,295 million as of September 2025. This approval validates Lupin's Pune-based biotech facility and its end-to-end biologic development capabilities. The company intends to leverage this approval to launch a broader portfolio of biosimilars in the coming years.
Key Highlights
Received U.S. FDA approval for Armlupeg™ (pegfilgrastim-unne) 6 mg/0.6 mL injection.
Targets the U.S. Pegfilgrastim market valued at approximately USD 1,295 million annually per IQVIA MAT Sept 2025.
Marks Lupin's first-ever biosimilar approval in the United States market.
Product will be manufactured at Lupin’s dedicated biotech facility in Pune, India.
Indicated for decreasing infection incidence in patients receiving myelosuppressive anti-cancer drugs.
💼 Action for Investors
This approval is a significant positive trigger that de-risks Lupin's biotech pipeline and opens a high-value revenue stream. Investors should monitor the commercial launch and market share capture in the competitive U.S. biosimilar space.